National Bank of Canada FI boosted its stake in shares of ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) by 100.0% during the third quarter, Holdings Channel reports. The fund owned 440 shares of the company's stock after acquiring an additional 220 shares during the period. National Bank of Canada FI's holdings in ShockWave Medical were worth $122,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Parallel Advisors LLC boosted its stake in shares of ShockWave Medical by 6.6% in the 2nd quarter. Parallel Advisors LLC now owns 938 shares of the company's stock valued at $179,000 after purchasing an additional 58 shares during the last quarter. Fifth Third Bancorp raised its position in shares of ShockWave Medical by 3.1% in the 2nd quarter. Fifth Third Bancorp now owns 2,084 shares of the company's stock valued at $398,000 after acquiring an additional 62 shares during the period. Lincoln National Corp raised its position in shares of ShockWave Medical by 6.6% in the 2nd quarter. Lincoln National Corp now owns 1,089 shares of the company's stock valued at $208,000 after acquiring an additional 67 shares during the period. Private Capital Group LLC raised its position in shares of ShockWave Medical by 42.0% in the 2nd quarter. Private Capital Group LLC now owns 257 shares of the company's stock valued at $49,000 after acquiring an additional 76 shares during the period. Finally, O Shaughnessy Asset Management LLC raised its position in shares of ShockWave Medical by 3.0% in the 2nd quarter. O Shaughnessy Asset Management LLC now owns 2,612 shares of the company's stock valued at $499,000 after acquiring an additional 77 shares during the period. Institutional investors own 90.56% of the company's stock.

Insider Activity

In other news, CEO Douglas Evan Godshall sold 30,000 shares of ShockWave Medical stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $240.81, for a total value of $7,224,300.00. Following the sale, the chief executive officer now directly owns 82,926 shares in the company, valued at $19,969,410.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Douglas Evan Godshall sold 30,000 shares of ShockWave Medical stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $240.81, for a total value of $7,224,300.00. Following the sale, the chief executive officer now directly owns 82,926 shares in the company, valued at $19,969,410.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Isaac Zacharias sold 4,000 shares of ShockWave Medical stock in a transaction that occurred on Wednesday, October 26th. The shares were sold at an average price of $292.44, for a total transaction of $1,169,760.00. Following the completion of the sale, the insider now owns 73,021 shares in the company, valued at $21,354,261.24. The disclosure for this sale can be found here. Insiders have sold 51,300 shares of company stock worth $12,615,504 over the last ninety days. Insiders own 3.90% of the company's stock.

ShockWave Medical Stock Performance

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SWAV. Morgan Stanley increased their price target on shares of ShockWave Medical from $255.00 to $290.00 and gave the company an "equal weight" rating in a research report on Tuesday, October 11th. Oppenheimer downgraded shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price target on the stock. in a research report on Tuesday, September 6th. Bank of America increased their price target on shares of ShockWave Medical from $260.00 to $310.00 in a research report on Monday, November 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ShockWave Medical in a research report on Friday, December 16th. They issued a "buy" rating and a $285.00 price target on the stock. Finally, Wells Fargo & Company downgraded shares of ShockWave Medical from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $300.00 to $235.00 in a report on Monday, December 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $258.22.

ShockWave Medical Company Profile

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Recommended Stories

• Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Is Kintara Therapeutics A Hidden Gem?
• Should You Warm up to Generac Stock for the Winter?

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating).

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.